Treatment of Rheumatoid Arthritis with Oral Type II Collagen / 대한류마티스학회지
The Journal of the Korean Rheumatism Association
;
: 149-156, 1999.
Article
in Korean
| WPRIM
| ID: wpr-157306
ABSTRACT
OBJECTIVE:
To investigate the efficacy and safety of oral bovine type II collagen (C II) in the treatment of rheumatoid arthritis (RA).METHODS:
Forty-five patients with active RA were enrolled and randomized to receive placebo or oral C II for 3 months. Efficacy parameters were assessed monthly. Cumulative response rates (percentages of patients meeting the criteria for response at anytime during the study) were analyzed utilizing 3 set of composite criteria Paulus criteria, ACR criteria for improvement in RA, and a requirement for > or = 30% reduction in both swollen and tender joint counts.RESULTS:
The C II-treated group (n=25) showed significant higher response rate by the Paulus criteria compared to placebo group (n=20, p=0.04), and MHAQ scores between baseline and 3 months of treatment were also significantly decreased in the C II-treated group (p<0.05). However, there were no significant differences in tender and swollen joint count, and physician and patient global scores between C II-treated and placebo groups. Only one patient treated with C II had a urticaria 1 week after administration, but no serious side effects were found in the two groups. Patients treated with C II (n=15) showed the decreased levels of circulating IgG antibodies to bovine C II 3 months after treatment (p=0.02), whereas significant changes of IgG antibodies to C II were not found in placebo group (n=12).CONCLUSION:
Oral administration of C II was safe and effective for the treatment of rheumatoid arthritis. The finding that serum IgG antibodies to bovine C II was decreased in patients who treated with C II suggest that autoimmune response to C II could be decreased by repetitive administration of C II.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Arthritis, Rheumatoid
/
Urticaria
/
Immunoglobulin G
/
Autoimmunity
/
Administration, Oral
/
Collagen Type II
/
Joints
/
Antibodies
Type of study:
Controlled clinical trial
Limits:
Humans
Language:
Korean
Journal:
The Journal of the Korean Rheumatism Association
Year:
1999
Type:
Article
Similar
MEDLINE
...
LILACS
LIS